HMOX1+ macrophages determine immunosuppressive microenvironment and immunotherapy efficacy in hepatocellular carcinoma
Macrophage-specific HMOX1 serves as a novel biomarker for predicting the efficacy of immunotherapy, and targeting HMOX1 has the potential to enhance the efficacy of anti-PD-1 therapy in HCC patients.
Authors
- Gu MeiYing
- Jialei Weng (ORCID: https://orcid.org/0000-0002-4916-0799)
- Xinlei Zhao (ORCID: https://orcid.org/0000-0002-6709-2961)
- Wenxin Xu (ORCID: https://orcid.org/0000-0002-8450-2037)
- Wei He (ORCID: https://orcid.org/0000-0003-4107-7285)
- Zhenkun Liu (ORCID: https://orcid.org/0000-0002-5722-3913)
- Peihao Wen (ORCID: https://orcid.org/0000-0002-4384-0558)
- Yating Liu (ORCID: https://orcid.org/0000-0002-6596-3532)
- Weiwei Hao (ORCID: https://orcid.org/0000-0002-9890-6024)
- Yabing Du
- Ruifeng Song
Institutions
- University of Cologne (DE)
- Fudan University (CN)
- Sir Run Run Shaw Hospital (CN)
- Zhongshan Hospital (CN)
- University Hospital Cologne (DE)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1097/hc9.0000000000000815
- Citations
- 1
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.80